Research & Literature

Guidelines for presymptomatic testing for Huntington's disease: past, present and future in France.

Clément S, Gargiulo M, Feingold J, Durr A

Revue neurologique 2015; (171(6-7)):572-80.

[Rehabilitation in Huntington's Disease].

Rollnik JD

Fortschritte der Neurologie-Psychiatrie 2015; (83(6)):334-43 doi:10.1055/s-0035-1553092.

Delayed identification and diagnosis of Huntington's disease due to psychiatric symptoms.

Pascu AM, Ifteni P, Teodorescu A, et al.

International journal of mental health systems 2015; (9()):33 doi:10.1186/s13033-015-0026-6.

Body composition analysis as an indirect marker of skeletal muscle mass in Huntington's disease.

Cubo E, Rivadeneyra J, Gil-Polo C, et al.

Journal of the neurological sciences 2015; (358(1-2)):335-8.

Genetic counseling and testing for Huntington's disease: A historical review.

Nance MA

American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2017; (174(1)):75-92 doi:10.1002/ajmg.b.32453.

Tetrabenazine: Spotlight on Drug Review.

Kaur N, Kumar P, Jamwal S, et al.

Annals of neurosciences 2016; (23(3)):176-185 doi:10.1159/000449184.

Genetic Contributors to Intergenerational CAG Repeat Instability in Huntington's Disease Knock-In Mice.

Neto JL, Lee JM, Afridi A, et al.

Genetics 2017; (205(2)):503-516 doi:10.1534/genetics.116.195578.

Juvenile Huntington's Disease: Diagnostic and Treatment Considerations for the Psychiatrist.

Quigley J

Current psychiatry reports 2017; (19(2)):9 doi:10.1007/s11920-017-0759-9.

[Huntington's Disease in Balearic Islands Population-Based Registry of Rare Diseases: Prevalence and Mortality during the Period 2010-2013. Spain].

Cáffaro Rovira M, Salom Castell MM

Revista espanola de salud publica 2017; (91()).

Glucose transportation in the brain and its impairment in Huntington disease: one more shade of the energetic metabolism failure?

Morea V, Bidollari E, Colotti G, et al.

Amino acids 2017; (49(7)):1147-1157 doi:10.1007/s00726-017-2417-2.

Motor outcome measures in Huntington disease clinical trials.

Reilmann R, Schubert R

Handbook of clinical neurology 2017; (144()):209-225 doi:10.1016/B978-0-12-801893-4.00018-3.

Huntington Disease: Genetics, Prevention, and Therapy Approaches.

Yapijakis C

Advances in experimental medicine and biology 2017; (987()):55-65 doi:10.1007/978-3-319-57379-3_6.

Valbenazine for the treatment of tardive dyskinesia.

Müller T

Expert review of neurotherapeutics 2017; (17(12)):1135-1144 doi:10.1080/14737175.2017.1386556.

Speech-Language Pathology Evaluation and Management of Hyperkinetic Disorders Affecting Speech and Swallowing Function.

Barkmeier-Kraemer JM, Clark HM

Tremor and other hyperkinetic movements (New York, N.Y.) 2017; (7()):489 doi:10.7916/D8Z32B30.

MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study.

Reed ER, Latourelle JC, Bockholt JH, et al.

Neurology 2018; (90(4)):e264-e272 doi:10.1212/WNL.0000000000004844.

Cognitive Performance and Apathy Predict Unemployment in Huntington's Disease Mutation Carriers.

Jacobs M, Hart EP, Roos RAC

The Journal of neuropsychiatry and clinical neurosciences 2018; (30(3)):188-193 doi:10.1176/appi.neuropsych.17070144.

Repeat expansion diseases.

Paulson H

Handbook of clinical neurology 2018; (147()):105-123 doi:10.1016/B978-0-444-63233-3.00009-9.

Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.

Niemann N, Jankovic J

Drugs 2018; (78(5)):525-541 doi:10.1007/s40265-018-0874-x.

Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease.

Dean M, Sung VW

Drug design, development and therapy 2018; (12()):313-319 doi:10.2147/DDDT.S138828.

Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington's disease.

Covey DP, Dantrassy HM, Yohn SE, et al.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2018; (43(10)):2056-2063 doi:10.1038/s41386-018-0107-8.

Perspectives on Genetic Testing and Return of Results from the First Cohort of Presymptomatically Tested Individuals At Risk of Huntington Disease.

Stuttgen KM, Bollinger JM, Dvoskin RL, et al.

Journal of genetic counseling 2018; (27(6)):1428-1437 doi:10.1007/s10897-018-0274-0.

Executive impairment is associated with unawareness of neuropsychiatric symptoms in premanifest and early Huntington's disease.

Andrews SC, Craufurd D, Durr A, et al.

Neuropsychology 2018; (32(8)):958-965 doi:10.1037/neu0000479.

Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis.

Fusilli C, Migliore S, Mazza T, et al.

The Lancet. Neurology 2018; (17(11)):986-993 doi:10.1016/S1474-4422(18)30294-1.

VMAT2 Inhibitors in Neuropsychiatric Disorders.

Tarakad A, Jimenez-Shahed J

CNS drugs 2018; (32(12)):1131-1144 doi:10.1007/s40263-018-0580-y.

Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations.

Mestre TA, Forjaz MJ, Mahlknecht P, et al.

Movement disorders clinical practice 2018; (5(2)):111-117 doi:10.1002/mdc3.12571.

Data Analytics from Enroll-HD, a Global Clinical Research Platform for Huntington's Disease.

Landwehrmeyer GB, Fitzer-Attas CJ, Giuliano JD, et al.

Movement disorders clinical practice 2017; (4(2)):212-224 doi:10.1002/mdc3.12388.

Apathy Is Related to Cognitive Control and Striatum Volumes in Prodromal Huntington's Disease.

Misiura MB, Ciarochi J, Vaidya J, et al.

Journal of the International Neuropsychological Society : JINS 2019; (25(5)):462-469 doi:10.1017/S1355617719000067.

The effects of huntingtin-lowering: what do we know so far?

Kaemmerer WF, Grondin RC

Degenerative neurological and neuromuscular disease 2019; (9()):3-17 doi:10.2147/DNND.S163808.

Brain structure in juvenile-onset Huntington disease.

Tereshchenko A, Magnotta V, Epping E, et al.

Neurology 2019; (92(17)):e1939-e1947 doi:10.1212/WNL.0000000000007355.

Predictive Genetic Counseling for Neurodegenerative Diseases: Past, Present, and Future.

Goldman JS

Cold Spring Harbor perspectives in medicine 2020; (10(7)) doi:10.1101/cshperspect.a036525.

Therapeutic Advances for Huntington's Disease.

Kumar A, Kumar V, Singh K, et al.

Brain sciences 2020; (10(1)) doi:10.3390/brainsci10010043.

Evaluating a genetic counseling narrative group session for people who have tested positive for the Huntington's disease expansion: An interpretative phenomenological analysis.

Spiers J, Smith JA, Ferrer-Duch M, et al.

Journal of genetic counseling 2020; (29(6)):1015-1025 doi:10.1002/jgc4.1229.

Psychological reactions to predictive genetic testing for Huntington's disease: A qualitative study.

Tillerås KH, Kjoelaas SH, Dramstad E, et al.

Journal of genetic counseling 2020; (29(6)):1093-1105 doi:10.1002/jgc4.1245.

Therapeutic strategies for Huntington's disease.

Estevez-Fraga C, Flower MD, Tabrizi SJ

Current opinion in neurology 2020; (33(4)):508-518 doi:10.1097/WCO.0000000000000835.

Presymptomatic Testing and Confidentiality in the Age of the Electronic Medical Record.

Black KJ, Barton SK, Perlmutter JS

The Journal of neuropsychiatry and clinical neurosciences 2021; (33(1)):80-83 doi:10.1176/appi.neuropsych.20030068.

Cell Replacement Therapy for Huntington's Disease.

Monk R, Connor B

Advances in experimental medicine and biology 2020; (1266()):57-69 doi:10.1007/978-981-15-4370-8_5.

DRPLA: understanding the natural history and developing biomarkers to accelerate therapeutic trials in a globally rare repeat expansion disorder.

Chaudhry A, Anthanasiou-Fragkouli A, Houlden H

Journal of neurology 2021; (268(8)):3031-3041 doi:10.1007/s00415-020-10218-6.

CAG repeat instability in embryonic stem cells and derivative spermatogenic cells of transgenic Huntington's disease monkey.

Khampang S, Parnpai R, Mahikul W, et al.

Journal of assisted reproduction and genetics 2021; (38(5)):1215-1229 doi:10.1007/s10815-021-02106-3.

Genetic and Environmental Contributors to Neurodegeneration: An Exploration of the Effects of Alcohol on Clinical Features of Huntington's Disease Using the Enroll-HD Global Platform.

Symonds AL, Macerollo A, Foy K, et al.

International journal of environmental research and public health 2021; (18(10)) doi:10.3390/ijerph18105113.

Juvenile Huntington's disease masquerading as progressive myoclonus epilepsy.

Thakor B, Jagtap SA, Joshi A

Epilepsy & behavior reports 2021; (16()):100470 doi:10.1016/j.ebr.2021.100470.

Enroll-HD: An Integrated Clinical Research Platform and Worldwide Observational Study for Huntington's Disease.

Sathe S, Ware J, Levey J, et al.

Frontiers in neurology 2021; (12()):667420 doi:10.3389/fneur.2021.667420.

[Identification of new factors inducing CTG.CAG repeat contractions in Myotonic Dystrophy type 1].

de Pontual L, Gourdon G, Tomé S

Medecine sciences : M/S 2021; (37 Hors série n° 1()):6-10 doi:10.1051/medsci/2021182.

Innovative Therapeutic Approaches for Huntington's Disease: From Nucleic Acids to GPCR-Targeting Small Molecules.

Komatsu H

Frontiers in cellular neuroscience 2021; (15()):785703 doi:10.3389/fncel.2021.785703.

Real-World Adherence to Tetrabenazine or Deutetrabenazine Among Patients With Huntington's Disease: A Retrospective Database Analysis.

Claassen DO, Ayyagari R, Garcia-Horton V, et al.

Neurology and therapy 2022; (11(1)):435-448 doi:10.1007/s40120-021-00309-5.

Utility of the Huntington's Disease Prognostic Index Score for a Perimanifest Clinical Trial.

Langbehn DR, Fine EM, Meier A, Hersch S

Movement disorders : official journal of the Movement Disorder Society 2022; (37(5)):1040-1046 doi:10.1002/mds.28944.

Improving Mood and Cognitive Symptoms in Huntington's Disease With Cariprazine Treatment.

Molnar MJ, Molnar V, Fedor M, et al.

Frontiers in psychiatry 2021; (12()):825532 doi:10.3389/fpsyt.2021.825532.

An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion.

Keller CG, Shin Y, Monteys AM, et al.

Nature communications 2022; (13(1)):1150 doi:10.1038/s41467-022-28653-6.

Huntington's disease influences employment before and during clinical manifestation: A systematic review.

van der Zwaan KF, Mentink MDC, Jacobs M, et al.

Parkinsonism & related disorders 2022; (96()):100-108 doi:10.1016/j.parkreldis.2022.02.022.

Dysphagia, Fear of Choking and Preventive Measures in Patients with Huntington's Disease: The Perspectives of Patients and Caregivers in Long-Term Care.

Kalkers K, Schols JMGA, van Zwet EW, Roos RAC

The journal of nutrition, health & aging 2022; (26(4)):332-338 doi:10.1007/s12603-022-1743-6.

Standardizing the CAP Score in Huntington's Disease by Predicting Age-at-Onset.

Warner JH, Long JD, Mills JA, et al.

Journal of Huntington's disease 2022; (11(2)):153-171 doi:10.3233/JHD-210475.

Huntington's Disease Regulatory Science Consortium: Accelerating Medical Product Development.

Turner EC, Gantman EC, Sampaio C, Sivakumaran S

Journal of Huntington's disease 2022; (11(2)):97-104 doi:10.3233/JHD-220533.

A biological classification of Huntington's disease: the Integrated Staging System.

Tabrizi SJ, Schobel S, Gantman EC, et al.

The Lancet. Neurology 2022; (21(7)):632-644 doi:10.1016/S1474-4422(22)00120-X.

Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities.

Tabrizi SJ, Estevez-Fraga C, van Roon-Mom WMC, et al.

The Lancet. Neurology 2022; (21(7)):645-658 doi:10.1016/S1474-4422(22)00121-1.

Complexities in Genetic Counseling and Testing of Huntington's Disease: A Perspective from India.

Ratna N, Pasupulati SL, Nadella RK, et al.

Neurology India 2022; (70(5)):2141-2144 doi:10.4103/0028-3886.359184.

Pharmacokinetic and Pharmacologic Characterization of the Dihydrotetrabenazine Isomers of Deutetrabenazine and Valbenazine.

Brar S, Vijan A, Scott FL, et al.

Clinical pharmacology in drug development 2023; (12(4)):447-456 doi:10.1002/cpdd.1205.

Salivary Huntingtin protein is uniquely associated with clinical features of Huntington's disease.

Parkin GM, Corey-Bloom J, Snell C, et al.

Scientific reports 2023; (13(1)):1034 doi:10.1038/s41598-023-28019-y.

Investigational treatments for neurodegenerative diseases caused by inheritance of gene mutations: lessons from recent clinical trials.

Imbimbo BP, Triaca V, Imbimbo C, Nisticò R

Neural regeneration research 2023; (18(8)):1679-1683 doi:10.4103/1673-5374.363185.

Therapeutic targeting of Huntington's disease: Molecular and clinical approaches.

Kumar D, Hasan GM, Islam A, Hassan MI

Biochemical and biophysical research communications 2023; (655()):18-24 doi:10.1016/j.bbrc.2023.02.075.

Ubiquitin-modifying enzymes in Huntington's disease.

Sap KA, Geijtenbeek KW, Schipper-Krom S, et al.

Frontiers in molecular biosciences 2023; (10()):1107323 doi:10.3389/fmolb.2023.1107323.

Applying the Huntington's Disease Integrated Staging System (HD-ISS) to Observational Studies.

Long JD, Gantman EC, Mills JA, et al.

Journal of Huntington's disease 2023; (12(1)):57-69 doi:10.3233/JHD-220555.

Di-valent siRNA-mediated silencing of MSH3 blocks somatic repeat expansion in mouse models of Huntington's disease.

O'Reilly D, Belgrad J, Ferguson C, et al.

Molecular therapy : the journal of the American Society of Gene Therapy 2023; (31(6)):1661-1674 doi:10.1016/j.ymthe.2023.05.006.

Huntington's Disease Clinical Trials Corner: August 2023.

Estevez-Fraga C, Tabrizi SJ, Wild EJ

Journal of Huntington's disease 2023; (12(2)):169-185 doi:10.3233/JHD-239001.

Plasma neurofilament light-chain and phosphorylated tau as biomarkers of disease severity in Huntington's disease: Korean cohort data.

Hwang YS, Oh E, Kim M, et al.

Journal of the neurological sciences 2023; (452()):120744 doi:10.1016/j.jns.2023.120744.

From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington's Disease Research.

Jiang A, Handley RR, Lehnert K, Snell RG

International journal of molecular sciences 2023; (24(16)) doi:10.3390/ijms241613021.

Longitudinal imaging highlights preferential basal ganglia circuit atrophy in Huntington's disease.

Liu CF, Younes L, Tong XJ, et al.

Brain communications 2023; (5(5)):fcad214 doi:10.1093/braincomms/fcad214.

The pathobiology of depression in Huntington's disease: an unresolved puzzle.

Jellinger KA

Journal of neural transmission (Vienna, Austria : 1996) 2024; (131(12)):1511-1522 doi:10.1007/s00702-024-02750-w.

A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease.

Aldous SG, Smith EJ, Landles C, et al.

Brain : a journal of neurology 2024; (147(5)):1784-1798 doi:10.1093/brain/awae063.

Treatment of Depression in Huntington's Disease: A Systematic Review.

Zadegan SA, Ramirez F, Reddy KS, et al.

The Journal of neuropsychiatry and clinical neurosciences 2024; (36(4)):283-299 doi:10.1176/appi.neuropsych.20230120.

Huntington's Disease: A Report of an Interesting Case and Literature Review.

Sharma PK, Aram A, Polaka Y, Pandian V

Cureus 2024; (16(3)):e55443 doi:10.7759/cureus.55443.

Stress in Huntington's Disease: Characteristics and Correlates in Patients and At-Risk Individuals.

Snow ALB, Ciriegio AE, Watson KH, et al.

Journal of Huntington's disease 2024; (13(2)):215-224 doi:10.3233/JHD-231515.

Huntington's Disease: Complex Pathogenesis and Therapeutic Strategies.

Tong H, Yang T, Xu S, et al.

International journal of molecular sciences 2024; (25(7)) doi:10.3390/ijms25073845.

Clinical Review of Juvenile Huntington's Disease.

Oosterloo M, Touze A, Byrne LM, et al.

Journal of Huntington's disease 2024; (13(2)):149-161 doi:10.3233/JHD-231523.

What Huntington's Disease Patients Say About Their Illness: An Online Direct-to-Participant Pilot Study.

Anderson KE, Arbatti L, Hosamath A, et al.

Journal of Huntington's disease 2024; (13(2)):237-248 doi:10.3233/JHD-231520.

Risk of VMAT2 inhibitors on suicidality and parkinsonism: report utilizing the United States Food and Drug Administration adverse event reporting system.

Wong S, Le GH, Kwan ATH, et al.

International clinical psychopharmacology 2025; (40(3)):176-181 doi:10.1097/YIC.0000000000000553.

Preclinical evaluation of stereopure antisense oligonucleotides for allele-selective lowering of mutant HTT.

Iwamoto N, Liu Y, Frank-Kamenetsky M, et al.

Molecular therapy. Nucleic acids 2024; (35(3)):102246 doi:10.1016/j.omtn.2024.102246.

Coping with Huntington's Disease in Patients and At-Risk Individuals.

Snow ALB, Ciriegio AE, Watson KH, et al.

Journal of Huntington's disease 2024; (13(3)):339-347 doi:10.3233/JHD-240027.

Skin Tau Quantification as a Novel Biomarker in Huntington's Disease.

Ruiz-Barrio I, Vázquez-Oliver A, Puig-Davi A, et al.

Movement disorders : official journal of the Movement Disorder Society 2024; (39(11)):2067-2074 doi:10.1002/mds.29989.

[Psychiatric symptoms of Huntington's disease].

Mühlbäck A, Hoffmann R, Pozzi NG, et al.

Der Nervenarzt 2024; (95(9)):871-884 doi:10.1007/s00115-024-01728-z.

Psychosocial impact on individuals who received negative test results from predictive testing for Huntington's disease: An exploratory qualitative study.

Osawa H, Matsukawa M, Yoshida A, et al.

Journal of genetic counseling 2025; (34(2)):e1981 doi:10.1002/jgc4.1981.

Pediatric Huntington Disease Brains Have Distinct Morphologic and Metabolic Traits: the RAREST-JHD Study.

Caligiuri ME, Tinelli E, Vizza P, et al.

Movement disorders clinical practice 2024; (11(12)):1592-1597 doi:10.1002/mdc3.14223.

Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice.

Caron NS, Byrne LM, Lemarié FL, et al.

Translational neurodegeneration 2024; (13(1)):50 doi:10.1186/s40035-024-00443-8.

An insight into allele-selective approaches to lowering mutant huntingtin protein for Huntington's disease treatment.

Yao JY, Liu T, Hu XR, et al.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2024; (180()):117557 doi:10.1016/j.biopha.2024.117557.

Apathy and Functional Status in Early-Stage Huntington's Disease.

Gibson JS, Hay KR, Claassen DO, et al.

The Journal of neuropsychiatry and clinical neurosciences 2025; (37(2)):125-130 doi:10.1176/appi.neuropsych.20230225.

Mutant huntingtin protein decreases with CAG repeat expansion: implications for therapeutics and bioassays.

Landles C, Osborne GF, Phillips J, et al.

Brain communications 2024; (6(6)):fcae410 doi:10.1093/braincomms/fcae410.

Valbenazine for the treatment of chorea associated with Huntington's disease.

Patino J, Furr Stimming E, Testa CM, Mehanna R

Expert opinion on pharmacotherapy 2025; (26(2)):127-132 doi:10.1080/14656566.2024.2445728.

Pharmacological Treatment of Neuropsychiatric Symptoms in Huntington's Disease: A Systematic Review.

Andriessen RL, Oosterloo M, Molema J, et al.

Movement disorders clinical practice 2025; (12(4)):418-431 doi:10.1002/mdc3.14343.

Antisense oligonucleotide-mediated MSH3 suppression reduces somatic CAG repeat expansion in Huntington's disease iPSC-derived striatal neurons.

Bunting EL, Donaldson J, Cumming SA, et al.

Science translational medicine 2025; (17(785)):eadn4600 doi:10.1126/scitranslmed.adn4600.

Neuraxial Analgesia and Anesthesia for Labor and Cesarean Delivery in a Patient with Juvenile Huntington Disease: A Case Report.

Soloniuk LJ, Jones J, Baker C, et al.

A&A practice 2025; (19(3)):e01926 doi:10.1213/XAA.0000000000001926.

Suicidal Ideation and Sleep Disturbances Among People With Huntington Disease: Evidence From the HDBOI Study.

Rodríguez Santana I, Frank SA, Mestre TA, et al.

Neurology. Clinical practice 2025; (15(3)):e200461 doi:10.1212/CPJ.0000000000200461.

Ayurvedic Management of Rare Genetic Condition-Huntington's Chorea: A Case Report.

Sharma M, Deshmukh S, Thakre T, et al.

Alternative therapies in health and medicine 2025;.

Vesicular monoamine transport inhibitors: current uses and future directions.

Rosenthal LS, Farag M, Aziz NA, Bang J

Lancet (London, England) 2025; (406(10503)):650-664 doi:10.1016/S0140-6736(25)01072-4.

How Early Does Anosognosia Begin in Huntington's Disease?

Bagga K, Xu A, Hall A, et al.

Movement disorders clinical practice 2025; (12(11)):1942-1946 doi:10.1002/mdc3.70342.

Comparison of tetrabenazine, tiapride and olanzapine in Huntington's disease: a one-year French randomized multicenter study (Neuro-HD).

Youssov K, Audureau E, Pariente J, et al.

Parkinsonism & related disorders 2025; (140()):108017 doi:10.1016/j.parkreldis.2025.108017.

Molecular and imaging biomarker responses to brain mutant HTT lowering in a mouse model of Huntington disease.

Caron NS, Fan J, Ma D, et al.

Molecular therapy. Nucleic acids 2025; (36(4)):102710 doi:10.1016/j.omtn.2025.102710.

The HEK293T cells manage overload by the overexpressed full-length Htt variants via proteasome activation.

Gotmanova NN, Bobik TV, Kriachkov VA, et al.

Biochimie 2026; (240()):59-75 doi:10.1016/j.biochi.2025.10.014.

Simple diameters, accurate stages:a practical approach to HD-ISS staging.

Heim B, Krismer F, Hemicker G, et al.

Journal of neurology 2025; (272(12)):760 doi:10.1007/s00415-025-13409-1.

Quantitative relationship between tominersen concentrations in cerebrospinal fluid and biomarker changes in Huntington's disease patients.

Yamamoto Y, Silber Baumann HE, Björnsson M, et al.

British journal of clinical pharmacology 2025; doi:10.1002/bcp.70367.

Huntington's disease clinical trials update: October 2025.

Farag M, Tabrizi SJ, Wild EJ

Journal of Huntington's disease 2026; (15(1)):156-166 doi:10.1177/18796397251399751.

AMT-130 gene therapy: a promising disease-modifying approach for Huntington's disease.

Mwape C, Qureshi AA, Saeed MZ, et al.

Annals of medicine and surgery (2012) 2026; (88(1)):1144-1145 doi:10.1097/MS9.0000000000004574.

Safety and efficacy of VMAT2 inhibitors in Huntington Disease: A systematic review.

Baghaei A, Dehnavi AZ, Hashempour Z, et al.

Parkinsonism & related disorders 2026; 108209 doi:10.1016/j.parkreldis.2026.108209.